Monoclonal antibodies for the treatment of migraine (migraneous)

Abstract

Introduction. Migraine is a syndromic condition characterized by headache’s crisis that occasionally disables people who have this illness. Currently, it is an onerous condition for health systems and conventional treatment is not totally effective in significant part of patients. Thus, therapies related to neuropeptides involved in the pathophysiology of the disease have been promising targets. Method. We used the Scielo and Pubmed databases, using combinations of descriptors: “migraine” and “monoclonal antibodies”. Results. In view of the ineffectiveness of traditional medicines used and their effects, monoclonal antibodies gain worldwide participation due to the ability to selectively target migraine-inducing cells. Calculate this selectivity, provide high safety, or low risk of drug interaction and no immunomodulatory effect, showing itself as a great alternative for the preventive treatment of migraine and with significant reduction of post-drome symptoms. However, the lack of response or relapse in some patients, points to an unsatisfactory understanding of pharmacokinetic and pharmacodynamic records, or that leads to a limited reduction or reduction. Conclusion. The commercialization of these drugs indicates promised results in the treatment and detection of migraine. However, the main thing that enters this therapeutic alternative is the high costs for its commercialization in comparison to traditional therapies.